Evotec SE has moved JST-018 into a first-in-human study while its two Accelerated Antibodies Program contracts carry combined potential value of up to $123.9 million. For investors, the milestone supports development of orthopoxvirus countermeasures and demonstrates the continuous-manufacturing model used for biodefense preparedness through clinical evaluation.

Key Highlights

  • JST-018 Manufacturing was completed at the J.POD Redmond Facility using continuous bioprocessing.
  • Evotec’s global team numbers around 4,500 people.
  • The study is registered on ClinicalTrials.gov under NCT07595458.

Evotec SE (NASDAQ: EVO) has moved JST-018, an investigational monoclonal-antibody cocktail against orthopoxviruses, into a first-in-human clinical study.

JST-018 Moves From Development to Clinical Testing

Just, Evotec Biologics took JST-018 from antibody sequence selection through preclinical work, process development, regulatory submission and cGMP production of trial material. Manufacturing took place at the J.POD Redmond facility using continuous bioprocessing. Study information is listed under ClinicalTrials.gov identifier NCT07595458.

2023 Contract Advances Biodefense Manufacturing

The program is the subsidiary’s second under the Accelerated Antibodies Program, following a 2022 award for plague antibodies. Evotec said the work demonstrates a scalable development and continuous-manufacturing model for biodefense preparedness.